Class / Patent application number | Description | Number of patent applications / Date published |
435184000 | Enzyme inactivation by chemical treatment | 61 |
20080199933 | Amine Oxidase Inhibitors - A therapeutic agent for selectively inhibiting amine oxidases associated diseases and conditions in humans includes at least one compound selected from the group consisting of propargylamines, polypropargylamines, homopropargylamines, 4-substituted-2-butynylamines, 2- and 3-halloallylamines, pyrroline derivatives, cycloalkenyl branched primary amines, propargyl diamines, homopropargyl amines and diamines, allenyl amines and diamines, chloroallyl diamines, lysyne analogues, β-haloamines, RF-substituted amines, RC | 08-21-2008 |
20080268516 | Target-Dependent Nucleic Acid Adapter - In accordance with the present invention, there is provided a nucleic acid target-dependent adapter linked to a nucleic acid sequence. The adapter comprises linked together a biosensor having a specific sequence complementary to a target sequence of a substrate, the biosensor improving the specificity of the nucleic acid sequence for the substrate, and a blocker stem sequence complementary to a portion of the nucleic acid sequence. In absence of the target sequence of the substrate, the blocker stem sequence forms an intramolecular stem with the nucleic acid sequence linked thereto, preventing exposition of the sequence of the nucleic acid sequence, thus locking the nucleic acid sequence so linked to the adapter in an inactive conformation, and in presence of the target sequence, the blocker stem sequence dissociating from the nucleic acid sequence, thus exposing the nucleic acid sequence linked to the adapter in an active conformation. | 10-30-2008 |
20080286847 | ALTERNATE MORPHEEINS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES - A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric protein has an assembly having a plurality of said units, wherein each of the units has a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms on a condition that in the multimeric protein (1) a structure of each of the units determines a structure of the different quaternary isoforms, (2) the units are in the equilibrium and (3) the structure of the different quaternary isoforms influences a function of the multimeric protein. | 11-20-2008 |
20080318293 | Sulfotransferase Inhibitors - A galactosamine derivative represented by the following formula (1): | 12-25-2008 |
20090042268 | IMINOSUGAR COMPOUNDS WITH ANTIFLAVIRUS ACTIVITY - An anti-viral compounds effective against viruses belonging to the Flaviviridae family, wherein the anti-viral compounds are 1,5-dideoxy-1,5-imino-D-glucitol derivative compounds having the general formula (I) | 02-12-2009 |
20090053786 | Prevention of disulfide bond reduction during recombinant production of polypeptides - The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures. | 02-26-2009 |
20090068718 | AMINO ACID DERIVATIVES OF INDOLINONE BASED PROTEIN KINASE INHIBITORS - Amino acid derivatives of pyrrolyl-indolinones and their amide or ester derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. | 03-12-2009 |
20090093038 | Method for the production of pure virally inactivated butyrylcholinesterase - The present invention provides a method for purifying butyrylcholinesterase from various biological fluids. Biological fluids include, e.g., blood, blood fractions, plasma, and bioreactor broths, and other such mixtures containing butyrylcholinesterase. In one embodiment, the invention provides a method for the production of purified, virally inactivated butyrylcholinesterase by contacting a biological fluid containing butyrylcholinesterase with a cationic exchange chromatography material, with an affinity chromatography material, and treating the fluid with solvent detergent. The resulting purified butyrylcholinesterase can also be subjected to a pasteurization step, and formulated in a sodium chloride/sodium phosphate solution for storage or lyophilization. | 04-09-2009 |
20090104677 | Heteroaromatic Selective Inhibitors of Neuronal Nitric Oxide Synthase - Compounds inhibiting neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, such compounds of a formula. | 04-23-2009 |
20090275099 | Methods and compositions for treating diseases and conditions associated with mitochondrial function - The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, mitochondrial F | 11-05-2009 |
20090275100 | COMPOSITIONS AND METHODS FOR ENHANCED SENSITIVITY AND SPECIFICITY OF NUCLEIC ACID SYNTHESIS - The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to “hot start” synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention. The invention also relates to using the inhibitors of the invention to prevent viral replication or treat viral infections in a subject. Thus, the invention relates to therapeutic methods and pharmaceutical compositions using the inhibitors of the invention. The invention thus may be used for in vivo and in vitro inhibition of nucleic acid synthesis and/or inhibition of polymerase activity. | 11-05-2009 |
20090305382 | ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS - Alkoxy indolinone based acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. | 12-10-2009 |
20100120118 | MRNA Interferase from Myxococcus Xanthus - A deployment of a toxin gene for developmental programmed cell death in bacteria is described. | 05-13-2010 |
20100136650 | MECHANISM-BASED INACTIVATORS OF AUTOTAXIN - A novel class of compounds to inactivate autotaxin enzymes is provided. Such compounds include mono- and di-fluoromethylphenyl C | 06-03-2010 |
20100190230 | Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability - Compounds and related compositions and methods as can be used to inhibit neuronal nitric oxide synthase and as can be employed in the treatment of various neurodegenerative diseases. | 07-29-2010 |
20100203613 | Aminopyridine Dimer Compounds, Compositions and Related Methods for Neuronal Nitric Oxide Synthase Inhibition - Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition. | 08-12-2010 |
20100209993 | PERMANENT INACTIVATION OF NUCLEASES - The present invention relates to the use of reagent for permanently inactivating nucleases wherein the reagent comprises an oxidizing agent, a protein denaturant and optionally a pH adjustor and to a method for permanently inactivating nucleases using said reagent. | 08-19-2010 |
20100261246 | METHOD FOR INHIBITING TELOMERASE REACTION - An object of the present invention is to provide a method for inhibiting a DNA extension reaction by telomerase. | 10-14-2010 |
20110027856 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful. | 02-03-2011 |
20110033911 | Episomal fusion gene - The present invention relates to an episomal structure expressing a functional oncogene, whereby said oncogene is a fusion gene of two chromosomal gene fragments. More specifically, the invention relates to a NUP214-ABL1 fusion product, important in the development of T-cell acute lymphoblastic leukemia, to methods to detect the fusion and to methods to prevent the oncogenic activity of said fusion product. | 02-10-2011 |
20110065162 | IRE-1alpha INHIBITORS - Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies. | 03-17-2011 |
20110111478 | Amides as Inhibitors of Human Secreted Phospholipase A2 - Methods and compounds useful for inhibiting a phospholipase A | 05-12-2011 |
20110159563 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase - Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity. | 06-30-2011 |
20110177577 | ENHANCEMENT OF VANADIUM-CONTAINING PHOSPHATASE INHIBITORS - The present invention is directed to a composition comprising a vanadium-containing phosphatase inhibitor and a polyol. In the presence of the polyol the effect of the inhibitor is enhanced, even in the presence of chelating agents or reducing agents. The invention also concerns the use of the inventive composition for inhibiting a phosphatase, as well as kits comprising the composition. | 07-21-2011 |
20110207197 | METHOD TO INHIBIT RIBONUCLEASE DICER, RIBONUCLEASE DICER INHIBITOR, AND USE OF RNA APTAMERS AS RIBONUCLEASE DICER INHIBITORS - The subject of the present invention is a method to inhibit ribonuclease Dicer, ribonuclease Dicer inhibitor, and use of RNA aptamers to inhibit ribonuclease Dicer. More specifically, this solution relates to using RNA aptamers as ribonuclease Dicer inhibitors that acts upon the competition basis (aptamers as competence inhibitors), use of RNA aptamers as allosteric ribonuclease Dicer inhibitors, and use of RNA aptamers as selective inhibitors of emergence of the selected miRNAs. | 08-25-2011 |
20110207198 | COMPOSITIONS AND METHODS FOR INHIBITING MMSET - The present invention relates to agents that find use in the treatment, management, and/or study of cancer. In particular, the present invention relates to agents (e.g., small molecules, nucleic acids) that affect MMSET expression or activity. | 08-25-2011 |
20110217753 | INHIBITORS OF EXTRACELLULAR PROTEASES - Provided is a plant derived extract including inhibitory activity against one or more extracellular proteases which degrade human tissue matrix. Moreover, the amount of inhibitory activity in an extract can be increased by stressing the plant prior to forming an extract. These extracts are each prepared by a process and demonstrate the ability to inhibit one or more extracellular proteases which degrade human tissue matrix. Libraries of extracts can be prepared from stressed and non-stressed plants, where each of the extracts demonstrate inhibitory activity against on or more extracellular protease inhibitors. Alternatively, semi-purified and purified inhibitory compounds can be isolated from the extracts. In one aspect, these extracts with inhibitory activity can be used during protein purification to minimize degradation due to extracellular proteases. | 09-08-2011 |
20110229954 | Nuclease Reduction - A method for reducing nuclease activity in a subtilisin solution obtained from a fermentation broth comprising a) adjusting the pH of the subtilisin solution to a pH in the range of from pH 8.5 to pH 10.5; b) adding a polyol; c) adjusting the temperature of the subtilisin solution to a temperature in the range of from 50° C. to 80° C.; whereby the nuclease activity is reduced to less than 5% of the initial value and the subtilisin activity is maintained at more than 80% of the initial value. | 09-22-2011 |
20110256606 | Methods and Compositions for Increasing Toxin Production - The invention provides methods and compositions (such as for example, culture media) for culturing | 10-20-2011 |
20110318807 | Small Molecule Inhibitors of Ghrelin O-Acyltransferase - Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules. Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition. | 12-29-2011 |
20120100592 | PIPEMIDIC ACID DERIVATIVE AUTOTAXIN INHIBITORS - Novel and optimized classes of pipemidic acid derivative compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes of compounds exhibit exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well. | 04-26-2012 |
20120258513 | Selective Neuronal Nitric Oxide Synthase Inhibitors - Compounds and related methods for selective inhibition of neuronal nitric oxide synthase over inducible and endothelial isoforms, such compounds as can provide reduced cationic character and enhanced bioavailability. | 10-11-2012 |
20120295323 | Inactivation of Proteases - The invention relates to a process for inactivating proteases by repeatedly changing the pH in the cell culture supernatant at the start of the process for the purification of biopharmaceuticals. The pH is adjusted first to 3-5, and then to 7-9. | 11-22-2012 |
20130040359 | Aminopyridine dimer compounds, compositions and related methods for neuronal nitric oxide synthase inhibition - Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition. | 02-14-2013 |
20130164813 | Method for Inhibiting Transglutaminase 2 Activity Using 2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine Derivatives - The present invention relates to a method for inhibiting transglutaminase 2 activity using 2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivatives. | 06-27-2013 |
20130164814 | CONTROL OF ENZYMES IN THE PRODUCTION OF PULP - A method and use therein for inactivating hydrogen peroxide decomposing enzymes in the production of recycled fiber pulp and/or mechanical pulp comprising providing solid peroxygen to an aqueous process for fiber production. | 06-27-2013 |
20130164815 | PROCESS FOR THE PRODUCTION OF A REVERSIBLY INACTIVE ACIDIFIED PLASMIN COMPOSITION - Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluded at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy. | 06-27-2013 |
20130224827 | ENDOTHELIAL NITRIC OXIDE SYNTHASE - The activity of endothelial nitric oxide synthase (eNOS) was modulated by contact with an effective amount of a mitogen-activated protein (MAP) kinase, resulting in phosphorylation of S602, T46, and/or S58. Kinetics and stoichiometry are disclosed. The contact strongly reduced nitric oxide (NO) synthesis, and also inhibited the cytochrome c reductase activity of eNOS reductase domains. Three sites of phosphorylation were determined that matched the serine-proline (SP) and threonine-proline (TP) motifs of typical MAP kinase phosphorylation sites. | 08-29-2013 |
20130288331 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS - Provided herein are compounds and methods of using same for the perturbation and/or inhibition of protein-protein interactions. Also provided herein is a data mining method useful for the identification of protein-protein interactions that may be inhibited by these compounds. | 10-31-2013 |
20130316432 | INHIBITORS OF EXTRACELLULAR PROTEASES - Provided is a plant derived extract including inhibitory activity against one or more extracellular proteases which degrade human tissue matrix. Moreover, the amount of inhibitory activity in an extract can be increased by stressing the plant prior to forming an extract. These extracts are each prepared by a process and demonstrate the ability to inhibit one or more extracellular proteases which degrade human tissue matrix. Libraries of extracts can be prepared from stressed and non-stressed plants, where each of the extracts demonstrate inhibitory activity against on or more extracellular protease inhibitors. Alternatively, semi-purified and purified inhibitory compounds can be isolated from the extracts. In one aspect, these extracts with inhibitory activity can be used during protein purification to minimize degradation due to extracellular proteases | 11-28-2013 |
20130344563 | NUCLEASE INHIBITORS AND METHODS FOR THEIR USE - A class of anionic oligomers and polymers that function for inhibition of nucleases, particularly RNase. Specific inhibitors include mixtures of oligomers of vinyl sulfate. Methods for inhibition or inactivation of one or more nucleases in vitro which comprises the step of contacting the one or more nucleases in a biological medium with one or more of the anionic oligomeric or polymeric inhibitors of this invention. Kits for carrying out a biological procedure, biological reaction and/or a biological assay containing one or more inhibitors of this invention. The use of oligomers and/or polymers of this invention as additives in buffers or reagents. The inhibitors of the invention can also be attached to surfaces to provide for removal of nucleases from media, solutions or other liquids in contact with the solid. | 12-26-2013 |
20140004590 | THIOXOTHIAZOLIDINE INHIBITORS | 01-02-2014 |
20140011254 | Nuclease Reduction - A method for reducing nuclease activity in a subtilisin solution obtained from a fermentation broth comprising
| 01-09-2014 |
20140073028 | MEK Ligands and Polynucleotides Encoding MEK Ligands - The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate MEK activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands. | 03-13-2014 |
20140106432 | CELL MASS CAPABLE OF SERVING AS A PRIMITIVE ORGAN-LIKE STRUCTURE COMPRISED OF A PLURALITY OF CELL TYPES OF SOMATIC ORIGIN - The present invention provides a method of producing a cell mass capable of serving as a primitive organ-like structure comprised of a plurality of somatic cell types of somatic origin, comprising: preparing cultures containing the plurality of types of somatic cells; mixing the plurality of types of somatic cell cultures followed by adding a Wnt signal activator to the mixed cell culture; subjecting the culture containing the Wnt signal activator to non-plate contact culturing over a predetermined time period; and replacing the medium of the culture cultured by the non-plate contact culturing with medium not containing Wnt signal activator and further culturing for a predetermined time period; wherein, at least one type of the plurality of somatic cells is maintained in an undifferentiated state. | 04-17-2014 |
20140147905 | Boronic and Borinic Acid Compounds as Inhibitors of Sulfenic Acid-Containing Proteins - A boronic or borinic acid compound is used to inhibit the activity of a sulfenic acid-containing protein. Thus, a biologically-active sulfenic acid-containing protein is contacted with an activity-inhibiting effective amount of a boronic or borinic acid compound of Formula I or a salt, hydrate or solvate thereof, whose components are disclosed within, and that contact is maintained for a time sufficient to inhibit the biological activity of the protein. | 05-29-2014 |
20140154772 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA - Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo. | 06-05-2014 |
20140234939 | Benzamide Compounds and Related Methods of Use - Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease. | 08-21-2014 |
20140256016 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors - Aminopyridine compounds, as can be used in conjunction with methods for modulation of nitric oxide synthase activity. | 09-11-2014 |
20140335590 | METHODS FOR PROMOTING CELL REPROGRAMMING - The present invention is based on the seminal discovery that several kinases play important roles in barrier pathways in somatic cell reprogramming. The present invention provides that modulating expression or activity of these kinases can significantly promote or enhance cell reprogramming efficiency. Key kinases are identified and key regulation networks involving such kinases are also identified that may be advantageously targeted to significantly increase reprogramming efficiency as well as direct differentiation of induced pluripotent stem (iPS) cells. | 11-13-2014 |
20140349368 | POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE - The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension. | 11-27-2014 |
20150056679 | METHOD OF ENZYME INACTIVATION - The present invention relates to a method for the inactivation of enzymes with a composition comprising a sulfonated peroxycarboxylic acid according to formula (I) wherein: R | 02-26-2015 |
20150087043 | MONOMERS CAPABLE OF MULTIMERIZING IN AN AQUEOUS SOLUTION THAT EMPLOY BIOORTHOGONAL CHEMISTRIES, AND METHODS OF USING SAME - Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins. | 03-26-2015 |
20150104846 | METHOD FOR PRESERVING COMPONENTS OF PANCREATIC JUICE IN A SAMPLE, AND KIT FOR PRESERVING COMPONENTS OF PANCREATIC JUICE IN A SAMPLE - The present invention provides a method for preserving biological components in pancreatic juice, and a kit suited for this method. The method involves adding, to a pancreatic juice-containing biological sample, at least one sulfonyl fluoride-containing protease inhibitor and at least one trypsin-like serine protease inhibitor belonging to a group of amino acid chloromethyl ketones. | 04-16-2015 |
20150140635 | Boronic and Borinic Acid Compound as Inhibitors of Sulfenic Acid-Containing Proteins - A boronic or borinic acid compound is used to inhibit the activity of a sulfenic acid-containing protein. Thus, a biologically-active sulfenic acid-containing protein is contacted with an activity-inhibiting effective amount of a boronic or borinic acid compound of Formula I or a salt, hydrate or solvate thereof, whose components are disclosed within, and that contact is maintained for a time sufficient to inhibit the biological activity of the protein. | 05-21-2015 |
20150290200 | INTRACELLULAR KINASE INHIBITORS - Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs. | 10-15-2015 |
20150337288 | BAULAMYCINS, COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein are compositions of compounds of formula (I), methods of inhibiting a bacterial infection by contacting a cell with a composition comprising a compound of formula (I), and methods of isolating compounds of formula (I) from an extract of Streptomyces tempisquensis. | 11-26-2015 |
20160076057 | INHIBITION OF METHANE AND HYDROGEN SULFIDE PRODUCTION IN ANAEROBIC DIGESTER ANIMAL FARMS, LANDFILLS, SEDIMENTS AND SEWER SYSTEMS - A method for inhibiting methane and hydrogen sulfide production from anaerobic digester systems and other biogas generating mediums disclosed. The biogas generating medium is contacted with an effective amount of a composition comprising red yeast rice and iron oxide to cause inhibition of methane and hydrogen sulfide production, and is useful in biogas generating medium from animal farms, including a swine, cattle or chicken farms. The method is useful to inhibit methane and hydrogen sulfide production in sewage systems, landfills, and sediment containing organic carbon. The disclosed inhibiting composition blocks 3-hydroxy-3-ethylglutaryl coenzyme A (HMG-CoA) reductase, and 8-hydroxy-5-deazaflavin (coenzyme F | 03-17-2016 |
20160152611 | SUBSTITUTED BENZAMIDE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | 06-02-2016 |
20160201028 | CELL CULTURE MEDIUM AND PROCESS FOR CONTROLLING a-AMIDATION AND/OR C-TERMINAL AMINO ACID CLEAVAGE OF POLYPEPTIDES | 07-14-2016 |
20160201049 | METHODS OF MODULATING UBIQUITIN LIGASE ACTIVITY | 07-14-2016 |